BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19261998)

  • 1. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia.
    Ikewaki K; Terao Y; Ozasa H; Nakada Y; Tohyama J; Inoue Y; Yoshimura M
    J Atheroscler Thromb; 2009 Mar; 16(1):51-6. PubMed ID: 19261998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
    Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
    Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
    Oka H; Ikeda S; Koga S; Miyahara Y; Kohno S
    Heart Vessels; 2008 Jul; 23(4):249-56. PubMed ID: 18649055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients.
    Ascer E; Bertolami MC; Venturinelli ML; Buccheri V; Souza J; Nicolau JC; Ramires JA; Serrano CV
    Atherosclerosis; 2004 Nov; 177(1):161-6. PubMed ID: 15488879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
    Ikejiri A; Hirano T; Murayama S; Yoshino G; Gushiken N; Hyodo T; Taira T; Adachi M
    Metabolism; 2004 Sep; 53(9):1113-7. PubMed ID: 15334369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
    Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia.
    Dimitrow PP; Jawień M
    Pharmacol Rep; 2010; 62(6):1250-4. PubMed ID: 21273686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
    Nozue T; Michishita I; Ito Y; Hirano T
    J Atheroscler Thromb; 2008 Jun; 15(3):146-53. PubMed ID: 18603821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
    Ushiroyama T; Nosaka S; Ueki M
    Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
    Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
    Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
    Korolenko TA; Tuzikov FV; Cherkanova MS; Johnston TP; Tuzikova NA; Loginova VM; Filjushina EE; Kaledin VI
    Can J Physiol Pharmacol; 2012 Feb; 90(2):141-53. PubMed ID: 22320860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
    Sánchez Muñoz-Torrero JF; Crespo L; Fernández Pereira L; Pereira G; Cámara C; Costo A
    Med Clin (Barc); 2011 Feb; 136(5):199-201. PubMed ID: 21145076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
    Yoshida H; Shoda T; Yanai H; Ikewaki K; Kurata H; Ito K; Furutani N; Tada N; Witztum JL; Tsimikas S
    Atherosclerosis; 2013 Jan; 226(1):161-4. PubMed ID: 23174369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.